End Stage Renal Disease (ESRD) Drug Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the end stage renal disease (esrd) drug market grown over the years?
Recent years have seen a sharp increase in the size of the end stage renal disease (ESRD) drug market. It is anticipated to escalate from $131.41 billion in 2024 to $149.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.1%. The previous growth can be credited to a rising prevalence of end stage renal disease, an expanding elderly population, better access to health care services, governmental actions and regulations, and a greater acceptance of renal replacement therapies.
What Is the forecasted market size and growth rate for the end stage renal disease (esrd) drug market?
The market size for end stage renal disease (ESRD) medications is anticipated to witness swift expansion in the upcoming years. Forecasted to rise to $268.44 billion in 2029 with a 15.7% compound annual growth rate (CAGR), this growth within the projected period is credited to the emergence of new therapies and medication advancements, heightened healthcare spending, escalating global incidences of chronic kidney illnesses, tailored medical strategies, regulatory backing, and expedited clearance processes. Key trends in the projection period encompass the escalating cases of end stage renal disease, progression in treatment methods, increasing concentration on precision medicine, the evolution of combined therapies, and the inclusion of technology within healthcare.
Get your end stage renal disease (esrd) drug market report here!
What are the major factors driving growth in the end stage renal disease (esrd) drug market?
The increasing prevalence of obesity and diabetes is predicted to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity refers to an excessive or irregular accumulation of fat that is detrimental to health, whereas diabetes is a long-term condition associated with the pancreas not producing sufficient insulin or the body’s inability to effectively use the produced insulin. For patients experiencing renal diseases, it’s crucial to manage fluid and electrolyte levels, blood pressure, and eliminate waste products through dialysis. This helps enhance overall health, potentially promoting weight loss and improving blood sugar levels. For example, World Obesity, a US-based organization focused on obesity research and management, projected in March 2022 that the global obesity figure could hit 892 million by 2025 and increase to 1,025 million by 2030. Furthermore, in February 2023, according to the National Health Service, a public healthcare system in the UK, it was projected that by 2030, the UK could see up to 5.5 million diabetes patients, implying nearly 9% of the population. Consequently, this surge in obesity and diabetes cases is expected to augment the ESRD drug market.
What key areas define the segmentation of the global end stage renal disease (esrd) drug Market?
The end stage renal disease (ESRD) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
What are the top market players propelling the growth of the end stage renal disease (esrd) drug industry?
Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
What are the key trends shaping the future of the end stage renal disease (esrd) drug market?
In the end-stage renal disease (ESRD) drug market, the trend of product innovation is crucial for gaining traction. Major corporations involved in the ESRD drug market are concentrating on creating innovative solutions to remain competitive. For instance, in April 2022, GlaxoSmithKline PLC, a pharmaceutical and biotechnology company from the UK, declared that the US Food and Drug Administration (FDA) has approved their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). This could potentially be used to treat patients with chronic kidney disease anaemia (CKD). The novelty of this product is rooted in the unprecedented Nobel prize-winning research which demonstrated how cells sense and adapt to changes in oxygen levels.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437
What regions are dominating the end stage renal disease (esrd) drug market growth?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Musculoskeletal Disorders Drugs Global Market Report 2022
Central Nervous System Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report
Cardiovascular Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
